当前位置：
X-MOL 学术
›
Lancet Respir. Med.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Airway inflammation enhances the effectiveness of elexacaftor–tezacaftor–ivacaftor therapy for cystic fibrosis and CFTRN1303K mutation
The Lancet Respiratory Medicine ( IF 38.7 ) Pub Date : 2024-10-09 , DOI: 10.1016/s2213-2600(24)00305-9 Martina Gentzsch, Charles R Esther Jr, Carla M P Ribeiro
The Lancet Respiratory Medicine ( IF 38.7 ) Pub Date : 2024-10-09 , DOI: 10.1016/s2213-2600(24)00305-9 Martina Gentzsch, Charles R Esther Jr, Carla M P Ribeiro
No Abstract
中文翻译：
气道炎症增强了 elexacaftor-tezacaftor-ivacaftor 治疗囊性纤维化和 CFTRN1303K 突变的有效性
无摘要
更新日期：2024-10-09
中文翻译：
气道炎症增强了 elexacaftor-tezacaftor-ivacaftor 治疗囊性纤维化和 CFTRN1303K 突变的有效性
无摘要
京公网安备 11010802027423号